Market Overview:
The global anti-retroviral drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of HIV/AIDS, rising demand for better treatment options, and growing awareness about HIV/AIDS and its treatment. Based on type, the global anti-retroviral drugs market is segmented into protease inhibitors, non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors, nucleoside analogs, and nucleoside reverse transcriptase inhibitors (NRTIs). NNRTIs are expected to witness the highest growth during the forecast period owing to their high efficacy and safety profile. Based on application, the global anti-retroviral drugs market is segmented into hepatitis B & C infections; HIV/AIDS; herpes simplex virus (HSV) infections; influenza A & B viruses; pneumococcal infections; meningitis caused by Haemophilus influenzae type b bacteria (Hib); tuberculosis (TB); and other applications. The hepatitis B & C infection segment is estimated to account for a major share of the global anti-retroviral drugs market in 2018 owing to high prevalence of these infections across regions.
Product Definition:
Anti-Retroviral Drugs are a class of medications that are used to treat HIV/AIDS. They work by preventing the virus from replicating in the body, which helps to keep the level of the virus down and allows the immune system to recover.
Protease Inhibitors:
Protease inhibitors are a class of drug that works by decreasing the activity of proteinases. They do this by binding to the active site on the enzyme and thus Inhibiting its action. The most common type of protease inhibitor is ritonavir, which is prescribed for HIV-1 infection as it prevents reverse transcriptase from being able to cleave off viral RNA from DNA in infected cells.
Non-Nucleoside Reverse Transcriptase Inhibitors:
Non-nucleoside reverse transcriptase inhibitors are the type of drugs used to treat HIV infection. They work by decreasing reverse transcriptase activity and hence prevent viral replication. The most commonly used drug class for treating HIV is the Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs).
Application Insights:
The application segment is sub-divided into HIV/AIDS, hepatitis, herpes, influenza and others. The HIV/AIDS segment dominated the market in 2017 owing to the increasing prevalence of AIDS and growing need for anti-retroviral drugs. According to UNAIDS Report 2016: Global Trends, around 37 million people were living with HIV across the globe. Moreover, an estimated 1.6 million people were diagnosed with AIDS in 2015 globally while about 397 thousand died due to it that year.
Regional Analysis:
The global anti-retroviral drugs market is expected to witness a CAGR of XX% over the forecast period, with the largest share being held by developed regions. This can be attributed to increasing government initiatives and awareness campaigns regarding HIV/AIDS, growing demand for new treatment options, and availability of effective treatment methods in this region. For instance, in December 2015; WHO & UNAIDS released a joint statement urging all Member States to increase their national response plans (NRP) under the HIV/AIDS action framework by 3-4 years until 2020.
Growth Factors:
- Increasing incidence of HIV/AIDS: The global prevalence of HIV is currently around 34 million people and it is estimated to grow to around 45 million by 2020. This will create a large pool of patients who would require anti-retroviral drugs for treatment.
- Rising awareness about HIV and its treatment: There has been a growing awareness about HIV in recent years, thanks to various campaigns by governments and NGOs. This has led to an increase in the number of people seeking diagnosis and treatment for the disease.
- Technological advancements: The development of new anti-retroviral drugs that are more effective and have fewer side effects is helping to improve the quality of life for patients living with AIDS/HIV infection .
- Growing demand from emerging markets: A large portion (around 60%)of the global demand for anti-retroviral drugs comes from developing countries where there is a high burden of HIV/AIDS cases .
Scope Of The Report
Report Attributes
Report Details
Report Title
Anti-Retroviral Drugs Market Research Report
By Type
Protease Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Integrase Inhibitors, Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
By Application
Hepatitis, HIV/AIDS, Herpes, Influenza, Others
By Companies
Cardionet, GE Healthcare, Abbott, AstraZeneca, Bristol-Myers-Squibb, Gilead, Cardiac Science Corp., Cardiocom, Biotelemetry, GlaxoSmithKline, Cardionet
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
156
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Anti-Retroviral Drugs Market Report Segments:
The global Anti-Retroviral Drugs market is segmented on the basis of:
Types
Protease Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Integrase Inhibitors, Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hepatitis, HIV/AIDS, Herpes, Influenza, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Cardionet
- GE Healthcare
- Abbott
- AstraZeneca
- Bristol-Myers-Squibb
- Gilead
- Cardiac Science Corp.
- Cardiocom
- Biotelemetry
- GlaxoSmithKline
- Cardionet
Highlights of The Anti-Retroviral Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Protease Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Integrase Inhibitors
- Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
- By Application:
- Hepatitis
- HIV/AIDS
- Herpes
- Influenza
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anti-Retroviral Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Anti-retroviral drugs are medications used to treat HIV. These drugs prevent the virus from replicating and spreading in the body.
Some of the key players operating in the anti-retroviral drugs market are Cardionet, GE Healthcare, Abbott, AstraZeneca, Bristol-Myers-Squibb, Gilead, Cardiac Science Corp., Cardiocom, Biotelemetry, GlaxoSmithKline, Cardionet.
The anti-retroviral drugs market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Anti-Retroviral Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Anti-Retroviral Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Anti-Retroviral Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Anti-Retroviral Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Anti-Retroviral Drugs Market Size & Forecast, 2020-2028
4.5.1 Anti-Retroviral Drugs Market Size and Y-o-Y Growth
4.5.2 Anti-Retroviral Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Protease Inhibitors
5.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors
5.2.3 Integrase Inhibitors
5.2.4 Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hepatitis
6.2.2 HIV/AIDS
6.2.3 Herpes
6.2.4 Influenza
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Anti-Retroviral Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Anti-Retroviral Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Protease Inhibitors
9.6.2 Non-Nucleoside Reverse Transcriptase Inhibitors
9.6.3 Integrase Inhibitors
9.6.4 Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hepatitis
9.10.2 HIV/AIDS
9.10.3 Herpes
9.10.4 Influenza
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Protease Inhibitors
10.6.2 Non-Nucleoside Reverse Transcriptase Inhibitors
10.6.3 Integrase Inhibitors
10.6.4 Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hepatitis
10.10.2 HIV/AIDS
10.10.3 Herpes
10.10.4 Influenza
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Protease Inhibitors
11.6.2 Non-Nucleoside Reverse Transcriptase Inhibitors
11.6.3 Integrase Inhibitors
11.6.4 Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hepatitis
11.10.2 HIV/AIDS
11.10.3 Herpes
11.10.4 Influenza
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Protease Inhibitors
12.6.2 Non-Nucleoside Reverse Transcriptase Inhibitors
12.6.3 Integrase Inhibitors
12.6.4 Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hepatitis
12.10.2 HIV/AIDS
12.10.3 Herpes
12.10.4 Influenza
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Protease Inhibitors
13.6.2 Non-Nucleoside Reverse Transcriptase Inhibitors
13.6.3 Integrase Inhibitors
13.6.4 Nucleoside Analogs and Nucleoside Reverse Transcriptase Inhibitors
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hepatitis
13.10.2 HIV/AIDS
13.10.3 Herpes
13.10.4 Influenza
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Anti-Retroviral Drugs Market: Competitive Dashboard
14.2 Global Anti-Retroviral Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Cardionet
14.3.2 GE Healthcare
14.3.3 Abbott
14.3.4 AstraZeneca
14.3.5 Bristol-Myers-Squibb
14.3.6 Gilead
14.3.7 Cardiac Science Corp.
14.3.8 Cardiocom
14.3.9 Biotelemetry
14.3.10 GlaxoSmithKline
14.3.11 Cardionet
